REYON PHARMACEUTICAL CO., LTD Logo

REYON PHARMACEUTICAL CO., LTD

Develops & makes APIs, generics, cell/gene therapies, and offers biopharma CDMO services.

102460 | KO

Overview

Corporate Details

ISIN(s):
KR7102460003
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로 620 에이동 12층 (대치동, 미래에셋타워), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Reyon Pharmaceutical Co., Ltd. is an integrated pharmaceutical company focused on the research, development, and manufacturing of both chemical and biopharmaceutical products. The company's core business includes the production of Active Pharmaceutical Ingredients (APIs) and finished generic formulations, such as injections, tablets, and antibiotics. Strategically expanding into next-generation therapeutics, Reyon is actively developing advanced treatments in areas like AAV gene therapy for conditions such as wet age-related macular degeneration (wAMD) and NK cell therapy for solid cancers. A significant part of its growth strategy involves its biopharmaceutical Contract Development and Manufacturing Organization (CDMO) services, which are being scaled through strategic partnerships to support the production of complex biologics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.5 MB
2025-08-01 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-07-25 00:00
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Korean 12.2 KB
2025-07-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 92.2 KB
2025-06-02 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.8 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.6 MB
2025-04-25 00:00
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Korean 10.9 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.3 KB
2025-03-24 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.1 MB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 20.0 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 629.3 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 14.8 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 1.1 MB
2025-03-14 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 1.0 MB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.9 KB

Automate Your Workflow. Get a real-time feed of all REYON PHARMACEUTICAL CO., LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for REYON PHARMACEUTICAL CO., LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for REYON PHARMACEUTICAL CO., LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.